How much revenue does Miltenyi Biotec make?

An industry retrospective reports Miltenyi Biotec had sales of 880 million euros in 2022 and was expected to top 1 billion euros for the first time in 2023, per BIO Deutschland. No independently verified 2025/2026 revenue figure exists.

Who owns Miltenyi Biotec?

Miltenyi Biotec is privately held and self-financed by founder Stefan Miltenyi since its 1989 founding. It has never taken outside venture capital and has never gone public, according to a BIO Deutschland company retrospective.

Is Miltenyi Biotec having layoffs in 2026?

No Miltenyi-specific layoffs were reported in 2025 or 2026 biopharma layoff trackers, even as the broader biopharma sector saw about 14,427 workers affected by layoffs in H1 2026, per BioSpace, July 16, 2026.

Could AI replace Miltenyi Biotec's business?

Unlikely soon. Miltenyi's core moat is proprietary MACS bead chemistry, FDA/EMA clinical clearances, and GMP manufacturing, not software. The live threat is microfluidics/AI-imaging cell sorting, growing about 13.4% CAGR while MACS still held roughly 35% of the technology mix in 2025 per Mordor Intelligence.

Who is Miltenyi Biotec's biggest competitor?

In clinical cell-therapy manufacturing, Lonza's Cocoon platform and Thermo Fisher's DynaCellect are the closest rivals to Miltenyi's CliniMACS Prodigy. Miltenyi and Lonza/Octane Biotech settled a six-patent infringement suit over Prodigy with prejudice on April 23, 2025.

Did Miltenyi Biotec win its lawsuit with Lonza?

The six-patent infringement case Lonza Walkersville and Octane Biotech brought against Miltenyi over CliniMACS Prodigy was dismissed with prejudice via joint motion on April 23, 2025, suggesting a negotiated settlement; terms were not disclosed.

Biotech tools companies · Germany

Miltenyi Biotec

miltenyibiotec.com ↗

German maker of magnetic cell sorting tools and CAR-T/CAR-NK manufacturing systems.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from May 2026 · Every call on the record Checkpoint: US government's answer due in Miltenyi's Court of International Trade tariff classification suit

The call

Miltenyi keeps winning new CAR-T and CAR-NK partnerships while Thermo Fisher and Lonza sell competing systems alongside it, with no visible customer losses yet.

Miltenyi Biotec makes machines and chemicals that help doctors and researchers separate and prepare cells for cancer treatments and other therapies. The company is hard to replace because hospitals and drug makers have already built their manufacturing processes around Miltenyi's technology, and getting FDA approval for a new method takes years. The main threat is that newer sorting methods using microfluidics and AI-powered imaging are growing faster than Miltenyi's current approach, and if Thermo Fisher or Lonza start winning major new cell-therapy manufacturing contracts away from Miltenyi in the next year or two, it could signal the beginning of a real shift in the market.

Why

AI pressure: Microfluidics and AI-assisted imaging cell sorters. AI-driven imaging sorters are growing faster than magnetic sorting but still hold a small slice of the market. Could AI do the core job? Unlikely.

Bigger players: Thermo Fisher (DynaCellect) and Lonza (Cocoon). Both rivals now sell closed automated cell therapy manufacturing systems that compete directly with CliniMACS Prodigy. Could a giant copy it? Probably.

What protects it. Proprietary MACS chemistry plus FDA/EMA clearances already built into approved CAR-T manufacturing workflows, which is costly to swap out mid-therapy.

What would change this call

A cell-therapy sponsor publicly switches from CliniMACS Prodigy to DynaCellect or Cocoon for a new program. Would show Thermo Fisher or Lonza is actually capturing CAR-T manufacturing share from Miltenyi.
Miltenyi's MACS-based cell sorting share reported below 30% in an annual market report. Would confirm microfluidics/AI-imaging sorting rivals are displacing MACS technology.
Outcome of the March 2026 CBP tariff lawsuit at the Court of International Trade. Would show whether tariff costs materially squeeze Miltenyi's US margins versus rivals.

Key numbers

Revenue about EUR 880 million (2022)
Over 18,000 products sold in 68 countries (n.d.)
More than 300 GMP manufacturing runs completed (2009-present)

Named risks

Microfluidics/AI-imaging sorting growing faster (13.4% CAGR) than MACS could erode its 35% share over years. Severity: medium
Thermo Fisher DynaCellect or Lonza Cocoon winning multiple high-profile CAR-T deals from CliniMACS Prodigy. Severity: medium
Founder Stefan Miltenyi is in his late 60s; no disclosed succession plan for founder-owned structure. Severity: medium
EU Medical Device Regulation raising compliance costs for instrument makers including Miltenyi. Severity: low
Pending 2026 CBP tariff/customs lawsuit outcome could raise import costs on products. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Lonza (Cocoon platform)	contesting	Patent suit over CliniMACS Prodigy dismissed with prejudice, April 23, 2025, settlement undisclosed
Thermo Fisher Scientific (DynaCellect)	contesting	Positioned as coexisting industry-standard closed system alongside CliniMACS Prodigy per 2026 market report
Danaher (Cytiva/Beckman Coulter)	contesting	Diversified life-science conglomerate competing adjacent to cell separation tools, 2026
Merck KGaA (MilliporeSigma) / Becton Dickinson	contesting	Listed among direct competitors in cell separation/analysis tools market, 2025-2026

Questions people ask

How much revenue does Miltenyi Biotec make?: An industry retrospective reports Miltenyi Biotec had sales of 880 million euros in 2022 and was expected to top 1 billion euros for the first time in 2023, per BIO Deutschland. No independently verified 2025/2026 revenue figure exists.
Who owns Miltenyi Biotec?: Miltenyi Biotec is privately held and self-financed by founder Stefan Miltenyi since its 1989 founding. It has never taken outside venture capital and has never gone public, according to a BIO Deutschland company retrospective.
Is Miltenyi Biotec having layoffs in 2026?: No Miltenyi-specific layoffs were reported in 2025 or 2026 biopharma layoff trackers, even as the broader biopharma sector saw about 14,427 workers affected by layoffs in H1 2026, per BioSpace, July 16, 2026.
Could AI replace Miltenyi Biotec's business?: Unlikely soon. Miltenyi's core moat is proprietary MACS bead chemistry, FDA/EMA clinical clearances, and GMP manufacturing, not software. The live threat is microfluidics/AI-imaging cell sorting, growing about 13.4% CAGR while MACS still held roughly 35% of the technology mix in 2025 per Mordor Intelligence.
Who is Miltenyi Biotec's biggest competitor?: In clinical cell-therapy manufacturing, Lonza's Cocoon platform and Thermo Fisher's DynaCellect are the closest rivals to Miltenyi's CliniMACS Prodigy. Miltenyi and Lonza/Octane Biotech settled a six-patent infringement suit over Prodigy with prejudice on April 23, 2025.
Did Miltenyi Biotec win its lawsuit with Lonza?: The six-patent infringement case Lonza Walkersville and Octane Biotech brought against Miltenyi over CliniMACS Prodigy was dismissed with prejudice via joint motion on April 23, 2025, suggesting a negotiated settlement; terms were not disclosed.

Timeline

2026-04-28CHA Biotech (Korea) partners with Miltenyi on CAR-NK manufacturing using its BaEV lentiviral vector platform
2026-03-16Miltenyi Biotec Inc. sues U.S. Customs and Border Protection over tariff classification at Court of International Trade
2025-09-25Miltenyi announces manufacturing support partnership with Verismo Therapeutics
2025-04-23Lonza/Octane Biotech six-patent suit against Miltenyi over CliniMACS Prodigy dismissed with prejudice
2024FDA guidance favors closed automated cell-therapy manufacturing systems like CliniMACS Prodigy
2022Miltenyi Biotec reports 880 million euro revenue, per BIO Deutschland retrospective
1989Stefan Miltenyi founds Miltenyi Biotec based on his invention of magnetic-activated cell sorting

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE